CMS Continues To Limit Coverage For NaF-18 PET Scans For Bone Metastases

There has been a lot of buzz around the new scanning contrasts that have come into limited usage for evaluating metastasized cancer cells that are in the bones. Despite the enthusiasm from the prostate and breast cancer communities, CMS (Medicare) continues to limit its financial coverage for PET scans using the contrast NaF-18 even though it has displayed an increased ability to detect bone metastases. In the past CMS, had been willing to pay for positron emission tomography or NaF-18 PET scans as long as physicians collected and reported the data on its use and put it into a clinical [...]